Sectors & IndustriesHealthcare

Best Healthcare Stocks to Buy Now (2026)

Top healthcare stocks in 2026 ranked by overall Due Diligence Score. See the best healthcare stocks to buy now, according to analyst forecasts for the healthcare sector.

According to Zen Ratings, our proprietary rating system that evaluates 115 factors proven to drive growth in stocks and assigns each stock in our system an overall letter grade as well as 7 individual Component Grades for Value, Growth, Momentum, Sentiment, Safety, Financials, and proprietary AI algorithms, the 3 best healthcare stocks to buy right now are:

Ironwood Pharmaceuticals (NASDAQ:IRWD) is the #1 top healthcare stock out of 1082 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Ironwood Pharmaceuticals (NASDAQ:IRWD) is: Value: A, Growth: B, Momentum: A, Sentiment: A, Safety: C, Financials: A, and AI: C.

Ironwood Pharmaceuticals (NASDAQ:IRWD) has a Due Diligence Score of 40, which is 14 points higher than the healthcare sector average of 26. It passed 13 out of 33 due diligence checks and has average fundamentals. Ironwood Pharmaceuticals has seen its stock return 112.61% over the past year, overperforming other healthcare stocks by 162 percentage points.

Ironwood Pharmaceuticals has an average 1 year price target of $6.50, an upside of 32.92% from Ironwood Pharmaceuticals's current stock price of $4.89.

Ironwood Pharmaceuticals stock has a consensus Buy recommendation according to Wall Street analysts. Of the 2 analysts covering Ironwood Pharmaceuticals, 0% have issued a Strong Buy rating, 50% have issued a Buy, 50% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Varex Imaging (NASDAQ:VREX) is the #2 top healthcare stock out of 1082 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Varex Imaging (NASDAQ:VREX) is: Value: B, Growth: A, Momentum: C, Sentiment: A, Safety: B, Financials: B, and AI: C.

Varex Imaging (NASDAQ:VREX) has a Due Diligence Score of 20, which is -6 points lower than the healthcare sector average of 26. Although this number is below the industry average, our proven quant model rates VREX as a "A".It passed 6 out of 33 due diligence checks and has weak fundamentals. Varex Imaging has seen its stock lose -0.36% over the past year, overperforming other healthcare stocks by 49 percentage points.

Varex Imaging has an average 1 year price target of $16.67, an upside of 19.56% from Varex Imaging's current stock price of $13.94.

Varex Imaging stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 3 analysts covering Varex Imaging, 66.67% have issued a Strong Buy rating, 33.33% have issued a Buy, 0% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Tactile Systems Technology (NASDAQ:TCMD) is the #3 top healthcare stock out of 1082 with a Zen Rating of A. Stocks with a rating of A have had an average return of +32.52% per year. Learn more.

The Component Grade breakdown for Tactile Systems Technology (NASDAQ:TCMD) is: Value: B, Growth: B, Momentum: B, Sentiment: A, Safety: C, Financials: A, and AI: C.

Tactile Systems Technology (NASDAQ:TCMD) has a Due Diligence Score of 50, which is 24 points higher than the healthcare sector average of 26. It passed 16 out of 33 due diligence checks and has strong fundamentals. Tactile Systems Technology has seen its stock return 60.69% over the past year, overperforming other healthcare stocks by 110 percentage points.

Tactile Systems Technology has an average 1 year price target of $27.00, a downside of -6.44% from Tactile Systems Technology's current stock price of $28.86.

Tactile Systems Technology stock has a consensus Strong Buy recommendation according to Wall Street analysts. Of the 4 analysts covering Tactile Systems Technology, 75% have issued a Strong Buy rating, 0% have issued a Buy, 25% have issued a Hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 68 healthcare stocks that have issued dividends in the past year, the 3 healthcare stocks with the highest dividend yields are:

Dominari Holdings (NASDAQ:DOMH) has an annual dividend yield of 25.19%, which is 23 percentage points higher than the healthcare sector average of 2.2%.

Dominari Holdings's dividend payout ratio of 8.4% indicates that its high dividend yield is sustainable for the long-term.

Spok Holdings (NASDAQ:SPOK) has an annual dividend yield of 9.08%, which is 7 percentage points higher than the healthcare sector average of 2.2%. Spok Holdings's dividend payout is not stable, having dropped more than 10% one times in the last 10 years. Spok Holdings's dividend has shown consistent growth over the last 10 years.

Spok Holdings's dividend payout ratio of 154.3% indicates that its high dividend yield might not be sustainable for the long-term.

Oramed Pharmaceuticals (NASDAQ:ORMP) has an annual dividend yield of 7.42%, which is 5 percentage points higher than the healthcare sector average of 2.2%.

Oramed Pharmaceuticals's dividend payout ratio of 0% indicates that its high dividend yield might not be sustainable for the long-term.

Healthcare stocks were down -0.56% in the last day, and down -2.51% over the last week. China Sxt Pharmaceuticals was the among the top losers in the healthcare sector, dropping -38% yesterday.

China SXT Pharmaceuticals shares are trading lower after the company announced a 1-for-150 reverse stock split.

Based on the Valuation rating, one of the 7 components of a stocks overall Zen Ratings grade, which evaluates factors including estimated earnings yield, earnings before interest and taxes/enterprise value, cash flow yield, free cash flow to price, and price-to-earnings growth (PEG ratio), the 3 most undervalued healthcare stocks right now are:

Harmony Biosciences Holdings (NASDAQ:HRMY) is the most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Harmony Biosciences Holdings has a valuation score of 71, which is 53 points higher than the healthcare sector average of 18. It passed 5 out of 7 valuation due diligence checks.

Harmony Biosciences Holdings's stock has dropped -7.64% in the past year. It has overperformed other stocks in the healthcare sector by 42 percentage points.

Bausch Health Companies (NYSE:BHC) is the second most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Bausch Health Companies has a valuation score of 57, which is 39 points higher than the healthcare sector average of 18. It passed 4 out of 7 valuation due diligence checks.

Bausch Health Companies's stock has dropped -23.06% in the past year. It has overperformed other stocks in the healthcare sector by 26 percentage points.

Organon & Co (NYSE:OGN) is the third most undervalued healthcare stock based on its Valuation Rating of A. Valuation is one of 7 Component Grades used to calculate the overall Zen Rating.

Organon & Co has a valuation score of 71, which is 53 points higher than the healthcare sector average of 18. It passed 5 out of 7 valuation due diligence checks.

Organon & Co's stock has dropped -46.52% in the past year. It has overperformed other stocks in the healthcare sector by 3 percentage points.

57.76% of healthcare stocks rated by analysts are a strong buy right now. On average, analysts expect healthcare stocks to rise by 37.41% over the next year.

8.1% of healthcare stocks have a Zen Rating of A (Strong Buy), 12.5% of healthcare stocks are rated B (Buy), 46.07% are rated C (Hold), 25.24% are rated D (Sell), and 8.1% are rated F (Strong Sell).